Provided by Tiger Trade Technology Pte. Ltd.

Amneal Pharmaceuticals, Inc.

11.85
-0.2100-1.74%
Post-market: 11.850.00000.00%17:20 EDT
Volume:1.15M
Turnover:13.65M
Market Cap:3.78B
PE:53.86
High:12.11
Open:12.01
Low:11.83
Close:12.06
52wk High:15.42
52wk Low:6.69
Shares:319.00M
Float Shares:191.00M
Volume Ratio:0.42
T/O Rate:0.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2200
EPS(LYR):0.2200
ROE:-881.26%
ROA:7.32%
PB:-53.40
PE(LYR):53.86

Loading ...

Amneal Pharmaceuticals Announces Plans to Launch Accessibility Index and Expand Efforts to Improve Medicine Affordability, Availability, Innovation, and Knowledge

Reuters
·
Jan 13

BRIEF-KeifeRX Announces Research Collaboration & Option Agreement With Amneal Pharmaceuticals

Reuters
·
Jan 10

Keiferx: Financial Terms of Agreement Were Not Disclosed

THOMSON REUTERS
·
Jan 10

Keiferx Announces Research Collaboration and Option Agreement With Amneal Pharmaceuticals to Advance Kfrx06, a Brain-Penetrant Lrrk2 Program for Parkinson’s Disease

THOMSON REUTERS
·
Jan 10

Amneal Pharmaceuticals Partners with KeifeRx to Advance LRRK2 Inhibitor for Parkinson’s Disease

Reuters
·
Jan 10

Truist Securities Adjusts Price Target on Amneal Pharmaceuticals to $15 From $14, Maintains Buy Rating

MT Newswires Live
·
Jan 07

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and Xgeva®

THOMSON REUTERS
·
Dec 23, 2025

Amneal Pharma - Expects to Commercialize Six Biosimilars by 2027

THOMSON REUTERS
·
Dec 23, 2025

FDA Approves Amneal and mAbxience Denosumab Biosimilars

Reuters
·
Dec 23, 2025

Amneal Pharmaceuticals (AMRX): Valuation Check After FDA Approval for New Epinephrine Injection

Simply Wall St.
·
Dec 21, 2025

The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following FDA Green Light For Hospital Epinephrine

Simply Wall St.
·
Dec 19, 2025

The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following Key FDA Wins For Epinephrine And Complex Generics

Simply Wall St.
·
Dec 11, 2025

FDA Approves Amneal Epinephrine Injection for U.S. Hospitals

Reuters
·
Dec 10, 2025

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

THOMSON REUTERS
·
Dec 10, 2025

Amneal Pharmaceuticals Initiated at Overweight by Barclays

Dow Jones
·
Dec 09, 2025

U.S. RESEARCH ROUNDUP-AstraZeneca, Confluent, Pepsico

Reuters
·
Dec 09, 2025

Amneal Reports Positive Interim Results for CREXONT in Parkinson’s Disease Trial

Reuters
·
Dec 05, 2025

Amneal Announces Positive Interim Phase 4 Elevate-Pd Results With Crexont® for Parkinson’s Disease

THOMSON REUTERS
·
Dec 05, 2025

Amneal Pharma: Elevate-Pd Study Is Ongoing With Longer-Term Data Expected in 2026

THOMSON REUTERS
·
Dec 05, 2025

Amneal Pharma - 55 Patients Show Substantial Benefit With Crexont

THOMSON REUTERS
·
Dec 05, 2025